Molecular Oncology Laboratory, Fundación Hospital General Universitario de Valencia, Valencia, Spain; CIBERONC, Valencia, Spain.
Biotechvana, Parc Cientific, Universitat de València, Paterna, Valencia, Spain.
Oral Oncol. 2021 May;116:105191. doi: 10.1016/j.oraloncology.2021.105191. Epub 2021 Feb 28.
To explore the pathophysiology of proliferative verrucous leucoplakia (PVL) through a methylated DNA immunoprecipitation and high-throughput sequencing (MeDIP-seq) case-control study.
Oral biopsies from ten PVL patients and five healthy individuals were obtained and used to compare their epigenetic patterns. Network biology methods and integrative analyses of MeDIP-seq and RNAseq data were applied to investigate functional relations among differentially methylated genes (DMGs). The value of selected genes as malignant biomarkers was evaluated in a large cohort of oral squamous cell carcinoma (OSCC) patients from TCGA.
A total of 4647 differentially methylated regions were found, with a prominent state of hypermethylation in PVL patients. At the gene level, differentially methylated regions (DMRs) covered 826 genes with distinct roles, including transcription factors and binding proteins with functions in cell adhesion, migration, proliferation, regulation of transcription, bone morphogenesis, and cell signalling. Network analysis revealed three major hubs, two of them collecting proteins related to the response of the patients to PVL and treatment and one hub collecting proteins related to PVL and cancer. The integrative analysis revealed 8 genes (ARTN, CD8A, GATA3, HOXD10, MYO7A, OSR2, PLCB1, and SPOCK2) significantly upregulated in PVL compared to control and 5 genes (ANKRD6, DLG2, GPX3, PITX2, and ZNF736) significantly downregulated. The status of de-regulation found for PVL patients was concordant with what was found for OSCC samples compared to normal adjacent tissue.
Our findings show the potential of methylation markers in PVL and suggest novel OSCC diagnostic biomarkers which may boost the development of novel epigenetic-based therapies.
通过甲基化 DNA 免疫沉淀和高通量测序(MeDIP-seq)病例对照研究探索增殖性疣状白斑(PVL)的病理生理学。
从 10 名 PVL 患者和 5 名健康个体中获得口腔活检组织,并将其用于比较其表观遗传模式。应用网络生物学方法和 MeDIP-seq 与 RNAseq 数据的综合分析,研究差异甲基化基因(DMGs)之间的功能关系。在 TCGA 中来自口腔鳞状细胞癌(OSCC)患者的大队列中评估所选基因作为恶性生物标志物的价值。
共发现 4647 个差异甲基化区域,PVL 患者表现出明显的高甲基化状态。在基因水平上,差异甲基化区域(DMRs)覆盖了 826 个具有不同作用的基因,包括转录因子和结合蛋白,其功能涉及细胞黏附、迁移、增殖、转录调控、骨形态发生和细胞信号转导。网络分析显示了三个主要枢纽,其中两个收集与患者对 PVL 和治疗的反应相关的蛋白质,一个枢纽收集与 PVL 和癌症相关的蛋白质。综合分析显示,与对照组相比,在 PVL 中上调的 8 个基因(ARTN、CD8A、GATA3、HOXD10、MYO7A、OSR2、PLCB1 和 SPOCK2)和下调的 5 个基因(ANKRD6、DLG2、GPX3、PITX2 和 ZNF736)显著上调。与正常相邻组织相比,在 OSCC 样本中发现了 PVL 患者的失调状态。
我们的研究结果表明了甲基化标记物在 PVL 中的潜在应用,并提出了新的 OSCC 诊断生物标志物,这可能会促进新型基于表观遗传的治疗方法的发展。